Chronic hepatitis C, depression and gender: a state of art

Advances in Dual Diagnosis

Volumn 8, Issue 4, 2015, Pages 193-210

  Martin Santos, Rocio ^a,b   Egmond, Elfi ^a,c   Cavero, Myriam ^a,b   Mariño, Zoe ^a   Subira, Susana ^c   Navines, Ricard ^a   Forns, Xavier ^a   Valdes, Manuel ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antidepressants; Breastfeeding; Chronic hepatitis C; Depression; Direct acting antivirals; Drug drug interactions; HIV; Inflammation; Interferon ; Pregnancy; Risk factors; Treatment

Indexed keywords

EID: 84948152778     PISSN: 17570972     EISSN: 20428324     Source Type: Journal    
DOI: 10.1108/ADD-05-2015-0009     Document Type: Review

References (121)

1. Adinolfi, L.E., Gambardella, M., Andreana, A., Tripodi, M.F., Utili, R. and Ruggiero, G. (2001), “Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity”, Hepatology, Vol. 33 No. 6, pp. 1358-64.
2. Airoldi, J. and Berghella, V. (2006), “Hepatitis C and pregnancy”, Obstetrical and Gynecological Survey, Vol. 61 No. 10, pp. 666-72.
3. Alexopoulou, A. and Karayiannis, P. (2015), “Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals”, Annals of Gastroenterology, Vol. 28 No. 1, pp. 55-65.
4. Alric, L., Fort, M., Izopet, J., Vinel, J.P., Charlet, J.P., Selves, J., Puel, J., Pascal, J.P., Duffaut, M. and Abbal, M. (1997), “Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection”, Gastroenterology, Vol. 113 No. 5, pp. 1675-81.
5. Arshad, M., El-Kamary, S.S. and Jhaveri, R. (2011), “Hepatitis C virus infection during pregnancy and the new-born period – are they opportunities for treatment?”, Journal of Viral Hepatitis, Vol. 18 No. 4, pp. 229-36.
6. Azzari, C., Indolfi, G., Betti, L., Moriondo, M., Massai, C., Becciolini, L., Bertelli, L., Poggi, G.M., De Martino, M. and Resti, M. (2007), “Vertical hepatitis C virus transmission is not related to mother-child class-1 HLA concordance”, International Journal of Immunopathology and Pharmacology, Vol. 20, pp. 827-31.
7. Babik, J.M., Cohan, D., Monto, A., Hartigan-O’Connor, D.J. and McCune, J.M. (2011), “The human foetal immune response to hepatitis C virus exposure in utero”, Journal of Infectious Diseases, Vol. 203 No. 2, pp. 196-206.
8. Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., Poordad, F., Goodman, Z.D., Sings, H.L., Boparai, N., Burroughs, M., Brass, C.A., Albrecht, J.K., Esteban, R. and HCV RESPOND-2 investigators (2011), “Boceprevir for previously treated chronic HCV genotype-1 infection”, New English Journal of Medicine, Vol. 364 No. 13, pp. 1207-17.
9. Bellentani, S., Pozzato, G., Saccoccio, G., Crovatto, M., Crocè, L.S., Mazzoran, L.A., Crovatto, M., Croce, L.S., Mazzoran, L., Masutti, F., Cristianini, G. and Tiribelli, C. (1999), “Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the dionysos study”, Gut, Vol. 44 No. 6, pp. 874-80.
10. Bennett, G.A., Velleman, R.D., Barter, G. and Bradbury, C. (2000), “Gender differences in sharing injecting equipment by drug users in England”, AIDS Care, Vol. 12, pp. 77-87.
11. Boscarino, J.A., Sitarik, A., Gordon, S.C., Rupp, L.B., Nerenz, D.R., Vijayadeva, V., Schmidt, M.A., Henkle, E. and Lu, M. (2014), “Risk factors for hepatitis C infection among Vietnam era veterans versus nonveterans: results from the Chronic Hepatitis Cohort Study (CHeCS)”, Journal of Community Health, Vol. 39 No. 3, pp. 914-21.
12. Brockington, I. (2011), “Maternal rejection of the young child: present status of the clinical syndrome”, Psychopathology, Vol. 44 No. 5, pp. 329-36.
13. Brunet, L., Moodie, E.E., Rollet, K., Cooper, C., Walmsley, S., Potter, M., Kelin, M.B. and Canadian Co-infection Cohort Investigators (2013), “Marijuana smoking does not accelerate progression of liver disease in HIV hepatitis C coinfection: a longitudinal cohort analysis”, Clinical Infectious Diseases, Vol. 57 No. 5, pp. 663-70.
14. Bull, S.J., Huezo-Diaz, P., Binder, E.B., Cubells, J.F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A.J., Norris, S., Cassidy, E., Aitchison, K.J., Miller, A.H. and Pariante, C.M. (2009), “Functional polymorphisms in the interleukin-6 and serotonin transporter genes and depression and fatigue induced by interferon-alpha and ribavirin treatment”, Molecular Psychiatry, Vol. 14 No. 7, pp. 1095-104.
15. Calabrese, F., Pontisso, P., Pettenazzo, E., Benvegnù, L., Vario, A., Chemello, L., Alberti, A. and Valente, M. (2000), “Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels”, Hepatology, Vol. 31 No. 5, pp. 1153-9.
16. Carrión, J.A., Gonzalez-Colominas, E., García-Retortillo, M., Cañete, N., Cirera, I., Coll, S., Gimenez, D., Marquez, C., Martin-Escudero, V., Castellvi, P., Navines, R., Castaño, J.R., Galeras, J.A., Salas, E., Bory, F., Martín-Santos, R. and Sola, R. (2013), “A multidisciplinary support programme increasses the efficiency of pegilated interferon alpha-2ª and ribavirin in hepatitis C”, Journal of Hepatology, Vol. 59 No. 5, pp. 926-33.
17. Castro, V.M., Clements, C.C., Murphy, S.N., Gainer, V.S., Fava, M., Weilburg, J.B., Erb, J.L., Churchill, S.E., Kohane, I.S., Iosifescu, D.V., Smoller, J.W. and Pertis, R.H. (2013), “QT interval and antidepressant use: a cross sectional study of electronic health records”, BMJ, Vol. 346, p. f288.
18. Codes, L., Asselah, T., Cazals-Hatem, D., Tubach, F., Vidaud, D., Paraná, R., Bedossa, P., Valla, D. and Marcellin, P. (2007), “Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy”, Gut, Vol. 56 No. 3, pp. 390-5.
19. Cox, J.L., Holden, J.M. and Sagovky, R. (1987), “Detection of postnatal depression. Development of the 10-items Edinburgh Postnatal Depression Scale”, British Journal of Psychiatry, Vol. 150, pp. 782-6.
20. Danese, A., Moffitt, T.E., Pariante, C.M., Ambler, A., Poulton, R. and Caspi, A. (2008), “Elevated inflammation levels in depressed adults with a history of childhood maltreatment”, Archives of General Psychiatry, Vol. 65 No. 4, pp. 409-15.
21. Dantzer, R., O’Connor, J.C., Freund, G.G., Johnson, R.W. and Kelley, K.W. (2008), “From inflammation to sickness and depression: when the immune system subjugates the brain”, National Reviews, Neuroscience, Vol. 9 No. 1, pp. 46-56.
22. Dunkelberg, J.C., Berkley, E.M., Thiel, K.W. and Leslie, K.K. (2014), “Hepatitis B and C in pregnancy: a review and recommendation for care”, Journal of Perinatology, Vol. 34 No. 12, pp. 882-91.
23. Durazzo, M., Belci, P., Collo, A., Prandi, V., Pistorne, E. and Martrana, M. (2014), “Gender specific medicine in liver diseases: a point of view”, World Journal of Gastroenterology, Vol. 20 No. 9, pp. 2127-35.
24. European Association for Study of Liver (2014), “EASL clinical practice guidelines: management of hepatitis C virus infection”, Journal of Hepatology, Vol. 60, pp. 392-420.
25. Evans, D.L., Charney, D.S., Lewis, L., Golden, R.N., Gorman, J.M., Krishnan, K.R., Nemeroff, C.B., Bremner, J.D., Carney, R.M., Coyne, J.C., Delong, M.R., Frasure-Smith, N., Glassman, A.H., Gold, P.W., Grant, I., Gwyther, L., Ironson, G., Johnson, R.L., Kanner, A.M., Katon, W.J., Kaufmann, P.G., Keefe, F.J., Ketter, T., Laughren, T.P., Leserman, J., Lyketsos, C.G., McDonald, W.M., McEven, B.S., Miller, A.H., Musselman, D., O’Connor, C., Petitto, J.M., Pollock, B.G., Robinson, R.G., Roose, S.P., Rwland, J., Sheline, Y., Sheps, D.S., Simon, G., Spiegel, D., Stunkard, A., Sunderland, T., Tibbits, P. Jr and Valvo, W.J. (2005), “Mood disorders in the medically ill: scientific review and recommendations”, Biological Psychiatry, Vol. 58 No. 3, pp. 175-89.
26. Everson, G.T., Sims, K.D., Rodriguez-Torres, M., Hézode, C., Lawitz, E., Bourlière, M., Loustand-Rati, V., Rustgi, V., Schwartz, H., Tatum, H., Marcelli, P., Pol, S., Thuluvath, P.J., Eley, T., Huang, S.P., McPhee, F., Wind-Rotolo, M., Chung, E., Pasquinelli, C., Grasela, D.M. and Gardiner, D.F. (2014), “Efficacy of an interferon and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection”, Gastroenterology, Vol. 146 No. 2, pp. 420-9.
27. Felguer, J.C. and Lotrich, F.E. (2013), “Inflammatory cytokines in depression: neurobiological mechanisms and therapeutical implications”, Neuroscience, Vol. 246 No. 8, pp. 199-229.
28. Fialho, R., Keller, M., File, A., Woods, C., Pereira, M., Yousseff, E., Tibble, J., Harrison, N., Fisher, M., Rusted, J. and Whale, R. (2014), “HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder”, Journal of International AIDS Society, Vol. 17 No. S3, p. 19629.
29. Figueiredo, F.P., Parada, A.P., Araujo, L.F., Silva, W.A. Jr and Del Ben, C.M. (2014), “The influence of genetic factors on peripartum depression: a systematic review”, Journal of Affective Disorders, Vol. 172 No. 10, pp. C265-73.
30. Fitzgerald, P., O’Brien, S.M., Scully, P., Rijkers, K., Scott, L.V. and Dinan, T.G. (2006), “Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression”, Psychological Medicine, Vol. 36 No. 1, pp. 37-43.
31. Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G.M., Stamataki, Z., Meredth, l.W., Rowe, I.A., Luo, G., Lopez-Ramirez, M.A., Baumert, T.F., Weksler, B., Couraud, P.Q., Kim, K.S., Romero, I.A., Jopling, C., Morgello, S., Balfe, P. and McKeating, J.A. (2012), “Hepatitis C virus infects the endotelial cells of the blood-brain barrier”, Gastroenterology, Vol. 142 No. 3, pp. 634-43.
32. Forns, X., Lawitz, E., Zeuzem, S., Gane, E., Bronowicki, J.P., Andreone, P., Horban, A., Brown, A., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., Scott, J., De La Rosa, G., Kalmeijer, R., Sinha, R. and Beumont-Mauviel, M. (2014), “Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype1 who relapsed after previous therapy: a phase 3 trial”, Gastroenterology, Vol. 146 No. 7, pp. 1669-79, e3.
33. Fried, M.W., Shiffman, M., Reddy, R., Marinos, G., Gonçales, F.L. JrHäussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J. and Yu, J. (2002), “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection”, New England Journal of Medicine, Vol. 347 No. 13, pp. 975-82.
34. Fried, M.W., Buti, M., Dore, G.J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikiti, I., Poordad, F., Sherman, M., Zeuzem, S., Scott, J., Gilles, L., Lenz, O., Peeters, M., Sekar, V., De Smedt, G., and Beumont-Mauviel, M. (2013), “Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype1 hepatitis C: the randomized PILLAR study”, Hepatology, Vol. 58 No. 6, pp. 1918-29.
35. Garg, A., van Heeswijk, R., Yang, Y., Kauffman, R., Smith, F. and Adda, N. (2012), “The Pharmacokinetic interaction between an oral contraceptive containing ethinylestradiol and norethindrone and the HCV protease inhibitor telaprevir”, Journal of Clinical Pharmacology, Vol. 52 No. 10, pp. 1574-83.
36. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., Qiu, P., Bertelsen, A.H., Muir, A.J., Sulkowski, M., McHutchison, J.G. and Goldstein, D.B. (2009), “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance”, Nature, Vol. 461 No. 12, pp. 399-401.
37. Gelabert, E., Subira, S., García-Esteve, L., Navarro, P., Plaza, A., Cuyas, E., Navinés, R., Gratacòs, M., Valdés, M. and Martín-Santos, R. (2012), “Perfectionism dimensions in major postpartum depression”, Journal of Affective Disorders, Vol. 136 Nos 1-2, pp. 17-35.
38. Gervais, A., Bacq, Y., Bernuau, J., Martinot, M., Auperin, A., Boyer, N., Kilani, A., Erlinger, S., Valla, D. and Marcellin, P. (2000), “Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C”, Journal of Hepatology, Vol. 32 No. 2, pp. 293-9.
39. Grebely, J., Page, K., Sacks-Davis, R., van der Loeff, M.S., Rice, T.M., Bruneau, J., Morris, M.D., Hajarizadeh, B., Amin, J., Cox, A.L., Kim, A.Y., McGovern, B.H., Schinkel, J., George, J., Shoukry, N.H., Lauer, G.M., Maher, L., Lloyd, A.R., Hellard, M., Dore, G.J., Prins, M. and InC3 Study Group (2014), “The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection”, Hepatology, Vol. 59 No. 1, pp. 109-20.
40. Gubbels, B. (2015), “Sex, the aging immune system, and chronic disease”, Cell Inmunology, Vol. 294, pp. 102-10.
41. Hayashida, K., Shoji, I., Deng, L., Jiang, D.P., Ide, Y.H. and Hotta, H. (2010), “17A-estradiol inhibits the production of infectious particles of hepatitis C virus”, Microbiology and Immunology, Vol. 54 No. 11, pp. 684-90.
42. Hickman, I.J., Clouston, A.D., Macdonald, G.A., Purdie, D.M., Prins, J.B., Ash, S., Jonsson, J.R. and Powell, E.E. (2002), “Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C”, Gut, Vol. 51 No. 1, pp. 89-94.
43. Hu, S.X., Kyulo, N.L., Xia, V.W., Hillebrand, D.J. and Hu, K.Q. (2009), “Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of US patients”, Journal of Clinical Gastroenterology, Vol. 43 No. 8, pp. 758-64.
44. Jans, L.A., Riedel, W.J., Markus, C.R. and Blokland, A. (2007), “Serotonergic vulnerability and depression: assumptions, experimental evidence and implications”, Molecular Psychiatry, Vol. 12 No. 6, pp. 522-43.
45. Lawitz, E., Lalezari, J.P., Hassanein, T., Kowdley, K.V., Poordad, F.F., Sheikh, A.M., Afdhal, N.H., Bernstein, D.E., Dejesus, E., Freilich, B., Nelson, D.R., Dieterich, D.T., Jacobson, I.M., Jensen, D., Abrams, G.A., Darling, J.M., Rodriguez-Torres, M., Reddy, K.R., Sulkowski, M.S., Bzowej, N.H., Hyland, R.H., Mo, H., Lin, M., Mader, M., Hindes, R., Albanis, E., Symonds, W.T., Berrey, M.M. and Muir, A. (2013), “Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial”, Lancet Infectious Diseases, Vol. 13 No. 5, pp. 401-8.
46. Lawitz, E., Sulkowski, M.S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z.M., Corregidor, A., DeJesus, E., Pearlman, B., Rabinovitz, M., Gitlin, N., Lim, J.K., Pockros, P.J., Scott, J.D., Fevery, B., Lambrecht, T., Ouwerkerk-Mahadevan, S., Callewaert, K., Symonds, W.T., Picchio, G., Lindsay, K.L., Beumont, M. and Jacobson, I.M. (2014), “Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study”, Lancet, Vol. 384 No. S9956, pp. 1756-65.
47. Lesurtel, M., Soll, C., Graf, R. and Clavien, P.A. (2008), “Role of serotonin in the hepatogastro intestinal tract: an old molecule for new perspectives”, Cellular and Molecular Life Sciences, Vol. 65 No. 6, pp. 940-52.
48. Levine, R.A., Sanderson, S.O., Ploutz-Snyder, R., Murray, F., Kay, E., Hegarty, J., Nolan, N., Kelleher, D., McDonald, G., OKeane, J.C. and Crowe, J. (2006), “Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D”, Clinical Gastroenterology and Hepatology, Vol. 4 No. 10, pp. 1271-7.
49. Liang, C., Chen, W., Zhi, X., Ma, T., Xia, X., Liu, H., Zhang, Q., Hu, Q., Zhang, Y., Bai, X. and Liang, T. (2013), “Serotonin promotes the proliferation of serum deprived hepatocellular carcinoma cells via up-regulation of FOXO3a”, Molecular Cancer, Vol. 12, p. 14.
50. Loftis, J.M., Huckans, M., Ruimy, S., Hinrichs, D.J. and Hauser, P. (2008), “Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha”, Neuroscience Letters, Vol. 430 No. 15, pp. 264-8.
51. Loustaud-Ratti, V., Stanke-Labesque, F., Marquet, P., Gagnieu, M.C., Maynard, M., Babany, G., Trepo, C. and French Ribavirin Group OPTIRIB (2009), “Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients”, Gastroentérologie clinique et biologique, Vol. 33 Nos 6-7, pp. 580-3.
52. Ly, K.N., Xing, J., Klevens, R.M., Jiles, R.B., Ward, J.W. and Holmberg, S.D. (2012), “The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007”, Annuals of Internal Medicine, Vol. 156 No. 4, pp. 271-8.
53. McHutchison, J.G., Lawitz, E.J., Shiffman, M.L., Muir, A.J., Galler, G.W., McCone, J., Nyberg, L.M., Lee, W.M., Ghalib, R.H., Schiff, E.R., Galati, J.S., Bacon, B.R., Davis, M.N., Mukhopadhyay, P., Koury, K., Noviello, S., Pedicone, L.D., Brass, C.A., Albrecht, J.K., Sulkowski, M.S. and IDEAL Study Team (2009), “Peginterferon alfa-2b or alfa-2b with ribavirin for treatment of hepatitis C infection”, New England Journal of Medicine, Vol. 362 No. 6, pp. 580-93.
54. Mallat, A., Hezode, C. and Lotersztajn, S. (2008), “Environmental factors as disease accelerators during chronic hepatitis C”, Journal of Hepatology, Vol. 48 No. 12, pp. 657-65.
55. Manzano-Robleda, M.C., Ornelas-Arroyo, V., Barrientos-Gutierrez, T., Méndez-Sánchez, N., Uribe, M. and Chávez-Tapia, N.C. (2015), “Boceprevir and telaprevir for chronic genotipe1 hepatitis C virus infection. A systematic review and meta-analysis”, Annals of Hepatology, Vol. 14, pp. 46-57.
56. Martino, V.D., Lebray, P., Myers, R.P., Pannier, E., Paradis, V., Charlotte, F., Moussalli, J., Thabut, D., Buffet, C. and Poynard, T. (2004), “Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure”, Hepatology, Vol. 40, pp. 1426-33.
57. Martin-Santos, R., Díez-Quevedo, C., Castellví, P., Navinés, R., Miquel, M., Masnou, H., Doler, A., Ardevol, M., Garcia, F., Galeras, J.A., Planas, R. and Sola, R. (2008), “De novo depression and anxiety disorders and influence on adherence during pegilated-alpha-2a-interferon and ribavirin treatment in patients with hepatitis C”, Alimentary Pharmacology and Therapeutics, Vol. 27 No. 7, pp. 257-65.
58. Martín-Santos, R., Gelabert, E., Subirà, S., Gutierrez-Zotes, A., Langorh, K., Jover, M., Torrens, M., Guillamat, R., Mayoral, F., Vanellas, F., Iborra, J.L., Grataos, M., Costas, J., Gonermann, I., Navines, R., Guitart, M., Roca, M., de Frutos, R., Vilella, E, Valdes, M., Esteve, L. and Sanjuan, J. (2012), “Is neuroticism a risk factor for postpartum depression?”, Psychological Medicine, Vol. 42 No. 3, pp. 1559-65.
59. Mast, E.E., Hwang, L.Y., Seto, D.S.Y., Nolte, F.S., Nainan, O.V., Wurtzel, H. and Alter, M.J. (2005), “Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy”, Journal of Infectious Diseases, Vol. 192 No. 11, pp. 1880-9.
60. Mekky, R.Y. and Abdelaziz, A.I. (2013), “Sex hormones and HCV: an unresolved mystery”, Expert Review of Gastroenterology and Hepatology, Vol. 7 No. 1, pp. 69-75.
61. Micallef, J.M., Kaldor, J.M. and Dore, G.J. (2006), “Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies”, Journal of Viral Hepatology, Vol. 13 No. 1, pp. 34-41.
62. Navarro, P., Garcia-Esteve, L., Ascaso, C., Aguado, J., Gelabert, E. and Martín-Santos, R. (2008), “Non-psychotic psychiatric disorders after childbirth: prevalence comorbidity in community sample”, Journal of Affective Disorders, Vol. 109 Nos 1-2, pp. 171-6.
63. Navines, R., Castellvi, P., Moreno-España, J., Gimenez, D., Udina, M., Cañizares, S., Diez-Quevedo, C., Valdés, M., Solà, R. and Martín-Santos, R. (2012), “Depressive and anxiety disorders in chronic hepatits C patients: reliability and validaty of the Patient Health Questionnaire”, Journal of Affective Disorders, Vol. 138 No. 3, pp. 343-51.
64. Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N., Freiich, B.F., Younes, Z.H., Harlan, W., Ghalib, R., Oguchi, G., Thuluvath, P.J., Ortiz-Lasanta, G., Rabinovitz, M., Bernestein, D., Bennett, M., Hawkins, T., Ravendhran, N., Sheikh, A.M., Varunok, P., Kowdley, K.V., Hennicken, D., McPhee, F., Rana, K., Hughes, E.A. and ALLY-3 Study Team (2015), “All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study”, Hepatology, Vol. 61 No. S4, pp. 1127-35.
65. Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G.S., Mauceri, B., Abate, G., Boemi, P., Di Pino, A., Ignaccolo, L., Vadalà, G., Misseri, M., Maiorca, D., Mastrosimone, G., Judica, A. and Palermo, F. (2010), “A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with interferon alpha and ribavirin”, Journal of Clinical Gastroenterology, Vol. 44 No. 9, pp. e210-7.
66. NICE Guidelines (2014), available at: www.nice.org.uk/guidance/cg192/resources/ (accessed 30 May 2015).
67. Ogasawara, S., Kage, M., Kosai, K., Shimamatsu, K. and Kojiro, M. (1993), “Hepatitis C virus RNA in saliva and breastmilk of hepatitis C carrier mothers”, Lancet, Vol. 341 No. S8844, pp. 561.
68. Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D. and Berenguer, J. (2002), “Contribution of obesity to hepatitis C-related fibrosis progression”, American Journal of Gastroenterology, Vol. 97 No. 9, pp. 2408-14.
69. Pecou, S., Moinard, N., Walschaerts, M., Pasquier, C., Daudin, M. and Bujan, L. (2009), “Ribavirin and pegylated interferon treatment for hepatitis C was associated not only with semen alterations but also with sperm deoxyribonucleic acid fragmentation in humans”, Fertility and Sterility, Vol. 91 No. S933, pp. e17-22.
70. Pocha, C., Knott, A., Rector, T.S. and Dieperink, E. (2014), “Are selective serotonin reuptake inhibitors associated with hepatocellular carcinoma in patients with hepatitis C?”, Journal of Clinical Psychiatry, Vol. 75 No. 10, pp. e1122-6.
71. Polis, C.B., Shah, S.N., Johnson, K.E. and Gupta, A. (2007), “Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis”, Clinical Infectious Diseases, Vol. 44 No. 8, pp. 1123-31.
72. Poynard, T., Mathurin, P., Chin-Lung, L., Guyader, D., Poupon, R., Tainturier, M.H., Myers, R.P., Muntenau, M., Ratziu, V., Manns, M., Vogel, A., Capron, F., Chedid, A., Bedossa, P. and PANFIBROSIS Group (2003), “A comparison of fibrosis progression in chronic liver disease”, Journal of Hepatology, Vol. 38 No. 3, pp. 257-65.
73. Prasad, M.R. and Honegger, J.R. (2013), “Hepatitis C virus in pregnancy”, American Journal of Perinatology, Vol. 30 No. 2, pp. 149-59.
74. Raison, C.L. and Miller, A.H. (2013), “The evolutionary significance of depression in pathogen host defense (PATHOS-D)”, Molecular Psychiatry, Vol. 18 No. 1, pp. 15-37.
75. Rao, H.Y., Sun, D.G., Jiang, D., Yang, R.F., Guo, F., Wang, J.H., Liu, F., Zhang, H.Y., Zhang, H.H., Du, S.C., Jin, Q., Qin, H., Lok, A.S. and Wei, L. (2012), “IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection”, Journal of Viral Hepatitis, Vol. 19 No. 3, pp. 173-81.
76. Reau, N.S. and Jensen, D.M. (2014), “Sticker shock and the price of new therapies for hepatitis C: Is it worth it?”, Hepatology, Vol. 59 No. 4, pp. 1246-9.
77. Reddick, K.L., Jhaveri, R., Gandhi, M., James, A.H. and Swamy, G.K. (2011), “Pregnancy outcomes associated with viral hepatitis”, Journal of Viral Hepatitis, Vol. 18 No. 7, pp. e394-8.
78. Resti, M., Azzari, C., Mannelli, F., Moriondo, M., Novembre, E., de Martino, M. and Vierucci, A. (1998), “Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany study group on hepatitis C virus infection”, British Medical Journal, Vol. 1998 No. S317, pp. 437-41.
79. Roberts, S.S., Miller, R.K., Jones, J.K., Lindsay, K.L., Greene, M.F., Maddrey, W.C., Williams, I.T., Liu, J. and Spiegel, R.J. (2010), “The Ribavirin Pregnancy Registry: findings after 5 years of enrollment, 2003-2009”, Birth defects research. Part A, Clinical and Molecular Teratology, Vol. 88 No. 7, pp. 551-9.
80. Rockstroch, J.K. and Bhagani, S. (2013), “Managing HIV/hepatitis C coinfection in the era of direct acting antivirals”, BMC Medicine, Vol. 11, p. 234.
81. Ruiz-Extremera, A., Muñoz-Gámez, J.A., Salmerón-Ruiz, M.A., de Rueda, P.M., Quiles-Pérez, R., Gila-Medina, A., Casado, J., Belen Martin, A., Sanjuan-Nuñez, L., Carazo, A., Pavón, E.J., Ocete-Hita, E., Leon, J. and Salmerón, J. (2011), “Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children”, Hepatology, Vol. 53 No. 6, pp. 1830-8.
82. Sangiovanni, A., Prati, G.M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., del Ninno, E., Morabito, A. and Colombo, M. (2006), “The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients”, Hepatology, Vol.43 No. 7, pp. 1303-10.
83. SanJuan, J., Martin-Santos, R., Garcia-Esteve, L., Carot, J.M., Guillamat, R., Gutierrez-Zotes, A., Gonermann, I., Canellas, F., Baca-Garcia, E., Jover, M., Navines, R., Valles, V., Vilella, E., de Diego, Y., Castro, J.A., Ivorra, J.L., Gelabert, E., Guitart, M., Labad, A., Mayoral, F., Roca, M., Gratacos, M., Costas, J., van Os, J. and de Frutos, R. (2008), “Mood changes after delivery: role of the serotonin transporter gene”, British Journal of Psychiatry, Vol. 193 No. 5, pp. 382-8.
84. Sarbah, S., Gramlich, T., Younoszai, A., Osmack, P., Goormastic, M., Grosso, L., Cooper, J.N., Di Bisceglie, A., Seneca, R. and Younossi, Z.M. (2004), “Risk factors for hepatocellular carcinoma in patients with cirrhosis”, Digestive Diseases and Sciences, Vol. 49 No. 5, pp. 850-3.
85. Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G.R., Kautz, A., Forton, D. and Pariente, C.M. (2012), “Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement”, Journal of Hepatology, Vol. 57 No. 6, pp. 1379-90.
86. Setiawan, V.W., Wilkens, L.R., Lu, S.C., Hernandez, B.Y., Le Marchand, L. and Henderson, B.E. (2015), “Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multi-ethnic cohort”, Gastroenterology, Vol. 148 No. 1, pp. 118-25.
87. Shepard, C.W., Finelli, L. and Alter, M.J. (2005), “Global epidemiology of hepatitis C virus infection”, Lancet Infectious Diseases, Vol. 5 No. 9, pp. 558-67.
88. Sims, O.T., Whalen, C.C., Nackerud, L.G. and Bride, B.E. (2014), “Longitudinal effects of selective serotonin reuptake inhibitor therapy and cytokine-related depression on hepatitis C viral logs during antiviral therapy”, Journal of Clinical Psychopharmacology, Vol. 34 No. 1, pp. 80-4.
89. Sobrino-Vegas, P., Monge Corella, S., Serrano-Villar, S., Gutiérrez, F., Blanco, J.R., Santos, I., del Romero, J., Segura, F., Portilla, J., Guillen, S.M., del Amo, J. and CoRIS (2014), “Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions”, PLoS One, Vol. 9 No. 12, p. e116226.
90. Sockalingam, S., Tseng, A., Giguere, P. and Wong, D. (2013), “Psychiatric treatment considerations with direct acting antivirals in hepatitis C”, BMG Gastroenterology, Vol. 13 p. 86.
91. Soll, C., Jang, J.H., Riener, M.O., Moritz, W., Wild, P.J., Graf, R. and Clavien, P.A. (2010), “Serotonin promotes tumor growth in human hepatocellular cancer”, Hepatology, Vol. 51 No. 4, pp. 1244-54.
92. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T. and Jacobson, I. (2014), “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection”, The New England Journal of Medicine, Vol. 370 No. 3, pp. 211-21.
93. Thomas, D.L., Thio, C.L., Martin, M.P., Qi, Y., Ge, D., O ' Huigin, C., Kidd, J., Kidd, K., Khakoo, S.I., Alexander, G., Goedert, J.J., Kirk, G.D., Donfield, S.M., Rosen, H.R., Tobler, L.H., Busch, M.P., McHutchison, J.G., Goldstein, D.B. and Carrington, M. (2009), “Genetic variation in IL28B and spontaneous clearance of hepatitis C virus”, Nature, Vol. 461, pp. 798-801.
94. Thomasson, H.R. (1995), “Gender differences in alcohol metabolism. Physiological responses to ethanol”, Recent Developments in Alcoholism, Vol. 12, pp. 163-79.
95. Thorpe, L.E., Ouellet, L.J., Levy, J.R., Williams, I.T. and Monterroso, E.R. (2000), “Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999”, Journal of Infectious Diseases, Vol. 182 No. 6, pp. 1588-94.
96. Tosone, G., Maraolo, A.E., Mascolo, S., Palmiero, G., Tambaro, O. and Orlando, R. (2014), “Vertical hepatitis V virus transmission: main questions and answers”, World Journal of Hepatology, Vol. 27 No. 8, pp. 538-48.
97. Turck, D., Vidailhet, M., Bocquet, A., Bresson, J.L., Briend, A., Chouraqui, J.P., Darmaun, D., Dupont, C., Frelut, M.L., Girardet, J.P., Goulet, O., Hankard, R., Rieu, D. and Simeoni, U. (2013), “Breastfeeding: health benefits for child and mother”, Archives de Pédiatrie, Vol. 20 No. S2, pp. S29-S40.
98. Udina, M., Castellvi, P., Moreno-España, J., Navines, R., Valdes, M., Forns, X., Langohr, K., Solà, R., Vieta, E. and Martín-Santos, R. (2012), “Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis”, Journal of Clinical Psychiatry, Vol. 73 No. 8, pp. 1128-38.
99. Udina, M., Hidalgo, D., Navines, R., Forns, X., Sola, R., Farre, M., Capuron, L., Vieta, E. and Martín-Santos, R. (2014), “Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis”, Journal of Clinical Psychiatry, Vol. 75 No. 10, pp. e1113-21.
100. Udina, M., Moreno-España, J., Navines, R., Gimenez, D., Langorh, K., Gratacos, M., Capuron, L., de la Torre, R., Sola., R. and Martin-Santos, R. (2013), “Serotonin and interleukin-6: the role of genetic polymorphism in IFN-induced neuropsychiatric symptoms”, Psychoneuroendocrinology, Vol. 38 No. 9, pp. 1803-13.
101. Valladares, G., Chacaltana, A. and Sjogren, M.H. (2010), “The management of HCV-infected pregnant women”, Annals of Hepatology, Vol. 9, pp. 92-7.
102. Van den Berg, C.H., Grady, B.P., Schinkel, J., van de Laar, T., Molenkamp, R., van Houdt, R., Coutinho, R.A., van Baarke, D. and Orins, M. (2011), “Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverts from a community-based cohort”, PLoS One, Vol. 6 No. 11, p. e27555.
103. Viitanen, P., Vartiainen, H., Aarnio, J., Vartiainen, H., Aarnio, J., von Gruenewaldt, V., Hakamäki, S., Lintonen, T., Mattila, A.K., Wuolijoki, T. and Joukamaa, M. (2011), “Hepatitis A,B,C and HIV infections among finnish female prisoners-young females a risk group”, The Journal of Infection, Vol. 62 No. 1, pp. 59-66.
104. Wedemeyer, H., Dore, G.J. and Ward, J.W. (2015), “Estimates on HCV disease burden worldwide-filling the gaps”, Journal of Viral Hepatitis, Vol. 22 No. S1, pp. 1-15.
105. Westbrook, R.H. and Dusheiko, G. (2014), “Natural history of hepatitis”, Journal of Hepatology, Vol. 61 No. S1, pp. S58-68.
106. White, D.L., Liu, Y., Garcia, J., El-Serag, H.B., Jiao, L., Tsavachidis, S., Franco, L.M., Lee, J.S., Tavakoli-Tabasi, S., Moore, D., Goldman, R., Kuzniarel, J., Ramsey, D.J., Kanwai, F. and Marcelli, M. (2014), “Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males”, International Journal of Molecular Epidemiology and Genetics, Vol. 5 No. 3, pp. 164-76.
107. Wilkinson, J., Radkowski, M., Eschbacher, J.M. and Laskus, T. (2010), “Activation of brain macrophages/microglia cells in hepatitis C infection”, Gut, Vol. 59 No. 10, pp. 1394-400.
108. Wu, J.Y., Shadbolt, B., Teoh, N., Blunn, A., To, C., Rodriguez-Morales, I., Chitturi, S., Kaye, G., Rodrigo, K. and Farrel, G. (2014), “Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C”, Journal of Gastroenterology and Hepatology, Vol. 29 No. 6, pp. 1258-64.
109. Xu, J.W., Gong, J., Chang, X.M., Luo, J.Y., Dong, L., Jia, A. and Xu, G.P. (2004), “Effects of estradiol on liver estrogen receptor and its mRNA expression in hepatic fibrosis in rats”, World Journal of Gastroenterology, Vol. 15 No. 2, pp. 250-4.
110. Yazdani Brojeni, P., Matok, I., Garcia Bournissen, F. and Koren, G. (2012), “A systematic review of the fetal safety of interferon alpha”, Reproductive Toxicology, Vol. 33 No. 9, pp. 265-8.
111. Yeung, C.Y., Lee, H.C., Chan, W.T., Jiang, C.B., Chang, S.W. and Chuang, C.K. (2014), “Vertical transmission of hepatitis C virus: current knowledge and perspectives”, World Journal of Hepatology, Vol. 27 No. 9, pp. 643-51.
112. Zeuzem, S., Berg, T., Gane, E., Ferenci, P., Foster, G.R., Fried, M.W., Hezode, C., Hirschfield, G.M., Jacobson, I., Nikitin, I., Pockros, P.J., Poordad, F., Scott, J., Lenz, O., Peeters, M., Sekar, V., De Smedt, G., Sinha, R. and Beumont-Mauviel, M. (2014), “Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial”, Gastroenterology, Vol. 146 No. 2, pp. 430-41, e6.
113. Available at: www.daylimed.nlm.nih.gov/ (accessed 30 May 2015).
114. Available at: http://ecdc.europa.eu/en/publications/ (accessed 30 May 2015).
115. Available at: www.hep-druginteractions.org/ (accessed 30 May 2015).
116. Available at: www.ribavirinpregnancyregistry.com/ (accessed 30 May 2015).
117. Anderson, G. and Maes, M. (2013), “Postpartum depression: psychoneuroimmunological underpinnings and treatment”, Neuropsychiatry Disease and Treatment, Vol. 9, pp. 277-87.
118. Boscarino, J.A., Lu, M., Moorman, A.C., Gordon, S.C., Rupp, L.B., Spradling, P.R., Teshale, E.H., Schmidt, M.A., Vijayadeva, V., Holmberg, S.D. and Chronic Hepatitis Cohort Study (CHeCS) Investigators (2015), “Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the chronic hepatitis cohort study (CHeCS)”, Hepatology, Vol. 61 No. 3, pp. 802-11.
119. Buresi, M.C., Lee, J., Gill, S., Kong, J.M., Money, D.M. and Yoshida, E.M. (2010), “The prevalence of gestational diabetes mellitus and glucose abnormalities in pregnant women with hepatitis C virus infection in British Columbia”, Journal of Obstetrics and Gynaecology Canada, Vol. 32 No. 10, pp. 935-41.
120. Ohfuji, S., Fukushima, W., Tanaka, T., Habu, D., Tamori, A., Sakaguchi, H., Takeda, T., Kawada, N., Seki, S., Nishiguchi, S., Shiomi, S. and Hirota, Y. (2006), “Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: a case-control study”, Hepatology Research, Vol. 36 No. 3, pp. 201-8.
121. Younossi, Z.M., Stepanova, M., Henry, L., Gane, E., Jacobson, I.M., Lawitz, E., Nelson, D., Gerber, L., Nader, F. and Hunt, S. (2014), “Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C”, Clinical Gastroenterology and Hepatology, Vol. 12 No. 8, pp. 1349-59, e13.